For patients with stage 2 or greater bladder cancer, care transitions linked with treatment delay
the ONA take:
According to a new study published in the Journal of Urology, researchers have found patients with stage 2 or higher urothelial carcinoma who underwent a care transition were more likely to experience a delay in treatment of 3 months or greater.
For the study, researchers sought to investigate whether changing hospitals between diagnosis and therapy for patients with muscle invasive bladder cancer would experience a delay in timely treatment. They identified 22,251 patients with stage 2 or greater urothelial carcinoma treated between 2003 and 2010 from the National Cancer Database.
Patients were considered to have underwent a care transition if they experienced a change in hospital between diagnosis of cancer and treatment with radical cystectomy or the initiation of neoadjuvant chemotherapy. Of all patients identified, 14.2% experienced a treatment delay of 3 months or more.
This proportion increased from 13.5% between 2003 and 2006 to 14.8% between 2007 and 2010 (P = 0.01). Of the patients who underwent a care transition, 19.4% experienced a treatment delay of 3 months or greater versus 10.7% who were diagnosed and treated at the same facility. The authors suggest that expediting care transitions at the time of hospital referral may improve the quality of care for patients with muscle invasive bladder cancer.
Patients with stage 2 or higher urothelial carcinoma who underwent care transition more likely to experience a delay in treatment.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|